Hims & Hers Health (HIMS) Stock Forecast, Price Target & Predictions
HIMS Stock Forecast
Hims & Hers Health stock forecast is as follows: an average price target of $16.00 (represents a -3.44% downside from HIMS’s last price of $16.57) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.
HIMS Price Target
The average price target for Hims & Hers Health (HIMS) is $16.00 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $5.00. This represents a potential -3.44% downside from HIMS's last price of $16.57.
HIMS Analyst Ratings
According to 15 Wall Street analysts, Hims & Hers Health's rating consensus is 'Buy'. The analyst rating breakdown for HIMS stock is 1 'Strong Buy' (6.67%), 9 'Buy' (60.00%), 5 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Hims & Hers Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | Allen Lutz | Bank of America Securities | $20.00 | $15.82 | 26.42% | 20.70% |
| Aug 27, 2024 | Daniel Grosslight | Citigroup | $20.00 | $14.93 | 34.00% | 20.70% |
| Aug 07, 2024 | Glen Santangelo | Jefferies | $18.00 | $16.04 | 12.22% | 8.63% |
| Aug 06, 2024 | George Hill | Deutsche Bank | $23.00 | $16.88 | 36.26% | 38.81% |
| May 22, 2024 | Maria Ripps | Canaccord Genuity | $24.00 | $17.56 | 36.67% | 44.84% |
| May 07, 2024 | Glen Santangelo | Jefferies | $14.00 | $12.35 | 13.36% | -15.51% |
| May 07, 2024 | Jailendra Singh | Truist Financial | $13.00 | $12.40 | 4.80% | -21.54% |
| May 07, 2024 | Korinne Wolfmeyer | Piper Sandler | $13.00 | $12.38 | 4.97% | -21.54% |
| May 07, 2024 | George Hill | Deutsche Bank | $16.00 | $11.65 | 37.34% | -3.44% |
| Apr 16, 2024 | Glen Santangelo | Jefferies | $15.00 | $13.22 | 13.46% | -9.47% |
The latest Hims & Hers Health stock forecast, released on Sep 13, 2024 by Allen Lutz from Bank of America Securities, set a price target of $20.00, which represents a 26.42% increase from the stock price at the time of the forecast ($15.82), and a 20.70% increase from HIMS last price ($16.57).
Hims & Hers Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 4 | 11 |
| Avg Price Target | $20.00 | $20.25 | $17.82 |
| Last Closing Price | $16.57 | $16.57 | $16.57 |
| Upside/Downside | 20.70% | 22.21% | 7.54% |
In the current month, the average price target of Hims & Hers Health stock is $20.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 20.70% increase as opposed to Hims & Hers Health's last price of $16.57. This month's average price target is down -1.23% compared to last quarter, and up 12.23% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 13, 2024 | Sandler O'Neill | Buy | Buy | Hold |
| Sep 13, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| Aug 27, 2024 | Citigroup | Neutral | Neutral | Hold |
| Aug 22, 2024 | Needham | - | Buy | Initialise |
| Aug 07, 2024 | Jefferies | Hold | Hold | Hold |
| Aug 06, 2024 | Deutsche Bank | Hold | Hold | Hold |
| Aug 06, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| Aug 06, 2024 | Sandler O'Neill | Buy | Buy | Hold |
| Aug 06, 2024 | Seaport Global | Buy | Buy | Hold |
| Jul 11, 2024 | Cowen & Co. | Buy | Buy | Hold |
Hims & Hers Health's last stock rating was published by Sandler O'Neill on Sep 13, 2024. The company gave HIMS a "Buy" rating, the same as its previous rate.
Hims & Hers Health Financial Forecast
Hims & Hers Health Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $246.62M | $226.70M | $207.91M | $190.77M | $167.20M | $144.84M | - | $101.31M | $84.70M | $74.17M | $60.69M | $52.31M | $41.47M |
| Avg Forecast | $539.15M | $522.83M | $515.86M | $508.56M | $509.76M | $482.66M | $452.47M | $433.27M | $418.91M | $379.30M | $304.66M | $270.37M | $246.47M | $220.08M | $204.95M | $179.08M | $161.17M | $130.32M | $103.89M | $91.23M | $76.79M | $70.53M | $56.49M | $48.71M | $37.00M |
| High Forecast | $547.14M | $530.58M | $523.50M | $516.10M | $517.32M | $489.82M | $459.18M | $439.70M | $425.12M | $384.49M | $309.18M | $274.38M | $247.45M | $223.34M | $207.99M | $181.73M | $163.56M | $132.26M | $103.89M | $92.07M | $77.50M | $71.18M | $57.01M | $49.16M | $37.34M |
| Low Forecast | $534.32M | $518.15M | $511.23M | $504.01M | $505.19M | $478.34M | $448.41M | $429.39M | $415.15M | $376.08M | $301.93M | $267.95M | $245.14M | $218.11M | $203.12M | $177.47M | $159.73M | $129.16M | $103.89M | $90.72M | $76.36M | $70.13M | $56.17M | $48.44M | $36.79M |
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.03% | 1.01% | 1.07% | 1.04% | 1.11% | - | 1.11% | 1.10% | 1.05% | 1.07% | 1.07% | 1.12% |
Hims & Hers Health's average Quarter revenue forecast for Mar 24 based on 4 analysts is $270.37M, with a low forecast of $267.95M, and a high forecast of $274.38M. HIMS's average Quarter revenue forecast represents a 9.63% increase compared to the company's last Quarter revenue of $246.62M (Dec 23).
Hims & Hers Health EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-400.00K | $-8.55M | $-9.24M | $-9.15M | $-11.61M | $-18.53M | - | $-15.62M | $-29.62M | $-17.57M | $-8.61M | $-50.92M | $-4.84M |
| Avg Forecast | $-166.02M | $-160.99M | $-158.84M | $-156.60M | $-156.97M | $-148.62M | $-139.32M | $-133.41M | $-128.99M | $-116.79M | $-93.81M | $-81.48M | $-75.89M | $-67.77M | $-63.11M | $-64.41M | $-49.63M | $-26.23M | $-31.99M | $-28.09M | $-22.01M | $-23.84M | $-11.63M | $-50.92M | $-11.39M |
| High Forecast | $-164.53M | $-159.55M | $-157.42M | $-155.19M | $-155.56M | $-147.29M | $-138.08M | $-132.22M | $-127.83M | $-115.80M | $-92.97M | $-65.19M | $-75.49M | $-67.16M | $-62.54M | $-51.53M | $-49.18M | $-20.98M | $-31.99M | $-27.93M | $-17.60M | $-19.07M | $-9.30M | $-40.74M | $-11.33M |
| Low Forecast | $-168.48M | $-163.38M | $-161.20M | $-158.92M | $-159.29M | $-150.83M | $-141.39M | $-135.39M | $-130.90M | $-118.39M | $-95.20M | $-97.78M | $-76.19M | $-68.77M | $-64.04M | $-77.30M | $-50.36M | $-31.47M | $-31.99M | $-28.35M | $-26.41M | $-28.61M | $-13.95M | $-61.10M | $-11.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.01% | 0.13% | 0.15% | 0.14% | 0.23% | 0.71% | - | 0.56% | 1.35% | 0.74% | 0.74% | 1.00% | 0.42% |
undefined analysts predict HIMS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Hims & Hers Health's previous annual EBITDA (undefined) of $NaN.
Hims & Hers Health Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $3.15M | $-7.57M | $-7.16M | $-10.07M | $-10.91M | $-18.84M | - | $-16.25M | $-31.16M | $-15.94M | $-9.15M | $-51.40M | $-5.23M |
| Avg Forecast | $39.58M | $42.88M | $41.81M | $42.21M | $40.45M | $37.48M | $31.80M | $28.90M | $27.20M | $24.58M | $10.47M | $-82.26M | $-5.24M | $-8.38M | $-11.38M | $-65.03M | $-13.75M | $-23.80M | $-18.63M | $-18.45M | $-23.15M | $-21.63M | $-12.36M | $-51.40M | $-35.64M |
| High Forecast | $40.34M | $43.71M | $42.61M | $43.03M | $41.23M | $38.21M | $32.41M | $29.46M | $27.72M | $40.96M | $10.67M | $-65.81M | $-2.62M | $-8.28M | $-11.25M | $-52.02M | $-13.59M | $-19.04M | $-18.63M | $-18.31M | $-18.52M | $-17.31M | $-9.89M | $-41.12M | $-35.38M |
| Low Forecast | $39.12M | $42.38M | $41.32M | $41.72M | $39.98M | $37.05M | $31.43M | $28.57M | $26.88M | $16.39M | $10.35M | $-98.71M | $-10.48M | $-8.54M | $-11.60M | $-78.03M | $-14.01M | $-28.56M | $-18.63M | $-18.67M | $-27.78M | $-25.96M | $-14.83M | $-61.68M | $-36.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.60% | 0.90% | 0.63% | 0.15% | 0.79% | 0.79% | - | 0.88% | 1.35% | 0.74% | 0.74% | 1.00% | 0.15% |
Hims & Hers Health's average Quarter net income forecast for Mar 24 is $-82.26M, with a range of $-98.71M to $-65.81M. HIMS's average Quarter net income forecast represents a -2713.85% decrease compared to the company's last Quarter net income of $3.15M (Dec 23).
Hims & Hers Health SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $158.21M | $151.98M | $138.36M | $127.76M | $113.11M | $126.46M | - | $91.67M | $83.66M | $82.53M | $64.68M | $88.66M | $36.52M |
| Avg Forecast | $539.75M | $523.41M | $516.43M | $509.13M | $510.32M | $483.20M | $452.97M | $433.75M | $419.37M | $379.72M | $305.00M | $141.87M | $246.74M | $220.32M | $205.18M | $112.15M | $161.35M | $123.21M | $104.00M | $91.34M | $62.16M | $70.61M | $56.55M | $48.77M | $37.04M |
| High Forecast | $547.75M | $531.17M | $524.08M | $516.68M | $517.89M | $490.36M | $459.69M | $440.18M | $425.59M | $384.91M | $309.52M | $170.24M | $247.72M | $223.59M | $208.22M | $134.58M | $163.74M | $147.85M | $104.00M | $92.17M | $74.59M | $71.26M | $57.07M | $49.22M | $37.38M |
| Low Forecast | $534.91M | $518.72M | $511.80M | $504.57M | $505.75M | $478.87M | $448.91M | $429.87M | $415.61M | $376.49M | $302.27M | $113.50M | $245.42M | $218.35M | $203.34M | $89.72M | $159.91M | $98.57M | $104.00M | $90.82M | $49.73M | $70.21M | $56.23M | $48.49M | $36.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.64% | 0.69% | 0.67% | 1.14% | 0.70% | 1.03% | - | 1.00% | 1.35% | 1.17% | 1.14% | 1.82% | 0.99% |
Hims & Hers Health's average Quarter SG&A projection for Mar 24 is $141.87M, based on 4 Wall Street analysts, with a range of $113.50M to $170.24M. The forecast indicates a -10.33% fall compared to HIMS last annual SG&A of $158.21M (Dec 23).
Hims & Hers Health EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.04 | $-0.03 | $-0.05 | $-0.05 | $-0.09 | - | $-0.08 | $-0.15 | $-0.08 | $-0.05 | $-0.34 | $-0.07 |
| Avg Forecast | $0.17 | $0.18 | $0.18 | $0.18 | $0.17 | $0.16 | $0.14 | $0.12 | $0.12 | $0.10 | $0.04 | $0.01 | $-0.02 | $-0.04 | $-0.05 | $-0.02 | $-0.06 | $-0.10 | $-0.08 | $-0.08 | $-0.09 | $-0.08 | $-0.08 | $-0.11 | $-0.16 |
| High Forecast | $0.17 | $0.19 | $0.18 | $0.18 | $0.18 | $0.16 | $0.14 | $0.13 | $0.12 | $0.17 | $0.05 | $0.01 | $-0.01 | $-0.04 | $-0.05 | $-0.02 | $-0.06 | $-0.10 | $-0.08 | $-0.08 | $-0.09 | $-0.08 | $-0.08 | $-0.11 | $-0.16 |
| Low Forecast | $0.17 | $0.18 | $0.18 | $0.18 | $0.17 | $0.16 | $0.13 | $0.12 | $0.11 | $0.07 | $0.04 | $0.01 | $-0.04 | $-0.04 | $-0.05 | $-0.02 | $-0.06 | $-0.10 | $-0.08 | $-0.08 | $-0.09 | $-0.08 | $-0.08 | $-0.11 | $-0.16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 0.71% | 2.36% | 0.90% | 0.91% | - | 0.96% | 1.69% | 1.00% | 0.60% | 3.14% | 0.44% |
According to undefined Wall Street analysts, Hims & Hers Health's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HIMS previous annual EPS of $NaN (undefined).
Hims & Hers Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GROV | Grove Collaborative | $1.41 | $150.00 | 10538.30% | Buy |
| NWL | Newell Brands | $7.83 | $16.70 | 113.28% | Hold |
| EL | Estée Lauder Companies | $84.56 | $176.72 | 108.99% | Hold |
| ELF | e.l.f. Beauty | $116.63 | $172.55 | 47.95% | Buy |
| COTY | Coty | $9.11 | $12.61 | 38.42% | Buy |
| IPAR | Inter Parfums | $117.54 | $157.00 | 33.57% | Buy |
| HNST | Honest Company | $4.00 | $4.25 | 6.25% | Buy |
| HIMS | Hims & Hers Health | $16.57 | $16.00 | -3.44% | Buy |
| KVUE | Kenvue | $23.39 | $22.00 | -5.94% | Buy |
| PG | Procter & Gamble Company | $174.08 | $156.05 | -10.36% | Buy |
| CL | Colgate-Palmolive Company | $105.73 | $90.75 | -14.17% | Buy |
HIMS Forecast FAQ
Is Hims & Hers Health a good buy?
Yes, according to 15 Wall Street analysts, Hims & Hers Health (HIMS) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 9 'Buy' recommendations, accounting for 66.67% of HIMS's total ratings.
What is HIMS's price target?
Hims & Hers Health (HIMS) average price target is $16 with a range of $5 to $24, implying a -3.44% from its last price of $16.57. The data is based on 15 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Hims & Hers Health stock go up soon?
According to Wall Street analysts' prediction for HIMS stock, the company can go down by -3.44% (from the last price of $16.57 to the average price target of $16), up by 44.84% based on the highest stock price target, and down by -69.82% based on the lowest stock price target.
Can Hims & Hers Health stock reach $20?
HIMS's highest twelve months analyst stock price target of $24 supports the claim that Hims & Hers Health can reach $20 in the near future.
What is Hims & Hers Health's current price target trend?
2 Wall Street analysts forecast a $20 price target for Hims & Hers Health (HIMS) this month, up 20.70% from its last price of $16.57. Compared to the last 3 and 12 months, the average price target increased by 22.21% and increased by 7.54%, respectively.
What are Hims & Hers Health's analysts' financial forecasts?
Hims & Hers Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.88B (high $1.91B, low $1.86B), average EBITDA is $-578M (high $-573M, low $-587M), average net income is $138.64M (high $141.31M, low $137.02M), average SG&A $1.88B (high $1.91B, low $1.86B), and average EPS is $0.59 (high $0.602, low $0.584). HIMS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.09B (high $2.12B, low $2.07B), average EBITDA is $-642M (high $-637M, low $-652M), average net income is $166.48M (high $169.69M, low $164.54M), average SG&A $2.09B (high $2.12B, low $2.07B), and average EPS is $0.709 (high $0.723, low $0.701).
Did the HIMS's actual financial results beat the analysts' financial forecasts?
Based on Hims & Hers Health's last annual report (Dec 2023), the company's revenue was $872M, beating the average analysts forecast of $850.58M by 2.52%. Apple's EBITDA was $-29.453M, missing the average prediction of $-271M by -89.14%. The company's net income was $-23.546M, missing the average estimation of $-90.027M by -73.85%. Apple's SG&A was $576.32M, missing the average forecast of $784.39M by -26.53%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.127 by -99.92%. In terms of the last quarterly report (Dec 2023), Hims & Hers Health's revenue was $246.62M, beating the average analysts' forecast of $246.47M by 0.06%. The company's EBITDA was $-400K, missing the average prediction of $-75.892M by -99.47%. Hims & Hers Health's net income was $3.15M, missing the average estimation of $-5.239M by -160.06%. The company's SG&A was $158.21M, missing the average forecast of $246.74M by -35.88%. Lastly, the company's EPS was $0, missing the average prediction of $-0.0223 by -100.00%